No CrossRef data available.
Article contents
Avonex® PEN Satisfaction and Patients Experience Clinical Trial
Published online by Cambridge University Press: 10 January 2017
Abstract
An abstract is not available for this content so a preview has been provided. As you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
![Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'](https://static-cambridge-org.ezproxyberklee.flo.org/content/id/urn%3Acambridge.org%3Aid%3Aarticle%3AS0317167100022642/resource/name/firstPage-S0317167100022642a.jpg)
- Type
- Letters to the Editor
- Information
- Copyright
- Copyright © The Canadian Journal of Neurological 1999
References
1.
Costello, K, Kennedy, P, Scanzillo, J. Recognizing nonadherence in patients with multiple sclerosis and maintaining treatment adherence in the long term.
Medscape J Med.
2008;10(9):225.Google Scholar
2.
Singer, B, Wray, S, Miller, T, et al. Patient-rated ease of use and functional reliability of an electronic autoinjector for self-injection of subcutaneous interferon beta-1a for relapsing multiple sclerosis.
Mult Scler Relat Disord. 2012;1:87–94.Google Scholar
3.
Lugaresi, A. Addressing the need for increased adherence to multiple sclerosis therapy: can delivery technology enhance patient motivation?
Expert Opin Drug Deliv. 2009;6(9):995–1002.Google Scholar
4.
Mikol, D, Lopez-Bresnaham, M, Taraskiewicz, S, Chang, P, Rangnow, J
(The Rebiject Study Group). A randomized, multicentre, open-label, parallel-group trial of the tolerability of interferon beta-la (Rebif®) administered by autoinjection or manual injection in relapsing-remitting multiple sclerosis.
Mult Scler. 2005;11:585–591.Google Scholar
5.
Phillips, JT, Fox, E, Grainger, W, Tuccillo, D, Liu, S, Deykin, A. An open-label, multicenter study to evaluate the safe and effective use of the single-use autoinjector with an AVONEX® prefilled syringe in multiple sclerosis patients.
BMC Neurol.
2011;11:126.Google Scholar